

Oncidium Foundation Launches Global 'RLT-Connect' Platform to Enhance Radioligand Therapy Access for Cancer Patients in Need

Brussels, September 8, 2023 — The Oncidium foundation proudly announces the launch of its RLT-Connect platform at the 2023 Annual Congress of the European Association of Nuclear Medicine (EANM). This innovative project facilitates radiopharmaceutical-based treatment donation worldwide, thereby expanding access to vital therapy for patients facing financial barriers.

Radioligand therapy (RLT) is a targeted medical treatment that uses radioactive molecules to selectively deliver radiation directly to cancer cells. More and more RLTs are under development, and their adoption is steadily increasing as ongoing research continues to demonstrate their potential benefits in improving patient outcomes.

In this context, the Oncidium foundation has initiated a significant effort by launching RLT-Connect, an online platform designed to facilitate collaboration between healthcare professionals seeking radioligand therapy for their patients who cannot afford it, and radioisotope suppliers willing to donate doses to make this life-saving treatment accessible to those in need. Furthermore, the foundation has committed to financing a portion of the treatments, ensuring that even more patients have the opportunity to receive the adequate care they require.

"Access to radiotheranostics is often constrained due to limited resources and logistical challenges." said Dr. Cecilia Carreras, Head of Nuclear Medicine and PET/CT at Ángeles Lomas Hospital, Mexico. "This platform will simplify the process, ensuring that we can provide the best care possible; thus, enabling the best of all worlds for everyone involved, and primarily for patients."

"In establishing 'RLT-Connect,' Oncidium foundation has forged a comprehensive ecosystem—a true chain of solidarity extending from therapy centers to radiopharmacies, and radioisotope suppliers—all united in pursuit of a common mission to ensure that every cancer patient has an equal opportunity to access a potentially life-saving technology, whoever and wherever they are." Said **Rebecca Lo bue, General manager of the Oncidium foundation.**

Currently, the platform is operational in pilot countries where the foundation received doses of two generous suppliers, Eczacıbaşı-Monrol and Isotopia Molecular Imaging. The foundation has entered into collaboration agreements with other prominent radioisotope suppliers in the market, including ITM and PanTera, and is actively engaged in ongoing discussions with additional suppliers, paving the way for its full-scale deployment in Q1, 2024.

"This life-saving project aligns perfectly with our commitment to advance the field of nuclear medicine." said Keren Eyal-Kotlizky, VP Business Development at Isotopia Molecular Imaging. "We are proud to partner with the Oncidium foundation in its endeavors to make radiotheranostics available for as many people as possible. We are delighted for the opportunity to contribute in making a difference in the lives of individuals who lack access to vital medical resources."

About the Oncidium foundation:

The Oncidium foundation is a nonprofit organization dedicated to advancing global access to radiotheranostics for cancer care, founded in 2011 by Dr. Richard Zimmermann. The foundation's priorities include raising awareness about radiotheranostics among patients and physicians, investing in research and scholarships, supporting, and financing the development of new radiopharmaceuticals for therapy, supporting clinical best practice, and improving access to patients, globally.

For more information visit www.ovidiumfoundation.org or the RLT-Connect platform: rlt-connect.ovidiumfoundation.org and follow Oncidium on [Twitter](#) and [LinkedIn](#).

For media inquiries and further information about RLT-Connect, please contact:
Floriane Laurent, floriane@ovidium-life.org